| Name | (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,(2S)-pyrrolidine-2-carboxylic acid |
|---|---|
| Synonyms |
L-proline compound with (3R,4R,5S,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (1:1)
L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol Ipragliflozin-002-L (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,(2S)-pyrrolidine-2-cboxylic acid D1060 Ipragliflozin L-proline L-Prolinecompd.with(1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol(1:1) Ipragliflozin (L-Proline) Azilstan Impurity 62 lpragliflozin L-Proline Ipragliflozin L-prolineQ: What is Ipragliflozin L-proline Q: What is the CAS Number of Ipragliflozin L-proline Q: What is the storage condition of Ipragliflozin L-proline Q: What e the applications of Ipragliflozin L-proline l-prolinecompd.with(1s)-1,5-anhydro-1-c-(3-(benzo(b)thien-2 ASP-1941 L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1) UNII-M6N3GK48A4 L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1)ChemicalBook l-prolinecompd (2S,3R,4R,5S,6R)-2-(3-(Benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (S)-Pyrrolidine-2-cboxylic acid |
| Description | Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. |
|---|---|
| Related Catalog | |
| Target |
IC50 value: 2.8 nM (SGLT2)[1][2]. |
| In Vitro | Ipragliflozin (L-Proline) potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases[3]. |
| In Vivo | Ipragliflozin (L-Proline) shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice [3]. Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h[4]. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance [5]. |
| References |
| Molecular Formula | C26H30FNO7S |
|---|---|
| Molecular Weight | 519.58200 |
| Exact Mass | 519.17300 |
| PSA | 167.72000 |
| LogP | 2.29790 |
| Storage condition | 2-8℃ |